Legend Biotech today opened a 31,000‑square‑foot research and development facility at 2300 Market Street in Philadelphia, Pennsylvania. The new center, which will house 55 full‑time scientists, engineers and support staff, marks the company’s first U.S. R&D site since its Piscataway, New Jersey, facility and expands its footprint in a major life‑sciences hub.
The Philadelphia hub is designed to accelerate research across Legend’s oncology and immunology portfolios and to support the next‑generation of cell‑therapy programs. By adding this facility, the company can scale its flagship CAR‑T product, CARVYKTI, and accelerate the development of future‑generation platforms that build on the same manufacturing and delivery expertise.
Philadelphia’s dense network of academic institutions and biotech companies provides a fertile environment for collaboration and talent acquisition. The new center will enable Legend to partner more closely with local universities and research groups, fostering joint projects that can translate into clinical advances and commercial opportunities.
"This new facility marks an exciting milestone for Legend Biotech as we continue to invest in our future and strengthen our leadership in cell‑therapy innovation," said CEO Ying Huang. President of Research and Development Guowei Fang added, "The opening of our new facility represents an exciting new chapter for our research organization, and our Philadelphia team will play a critical role in advancing our sustainable pipeline of innovative cell therapies while strengthening collaborations within one of the nation’s most dynamic biotech ecosystems."
The investment signals Legend’s commitment to growth and its ambition to remain a leader in the competitive cell‑therapy market. By expanding its R&D infrastructure, the company aims to maintain a robust pipeline, attract top talent, and accelerate the commercialization of its therapies, positioning it for long‑term success in the rapidly evolving field of cell‑based medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.